Interestingly, before B cell reconfiguration, autoantigen-specific CD4+ T cells respond more firmly to islet-specific antigens ex vivo [39, 40], which identifies clinical responders to rituximab treatment in patients with T1D [40]. The gene discussed is CD4; the disease is type 1 diabetes mellitus.